Forty years of cancer modelling in the mouse

European Journal of Cancer

Volumn 40, Issue 13, 2004, Pages 1974-1980

  Hirst, G L ^a   Balmain, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Carcinogenesis; Genetic susceptibility; Imaging; Knockout; Mouse models; Preclinical; Transgenic; Tumour promotion

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT;

ACCURACY; CANCER DIAGNOSIS; CANCER MODEL; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; DIAGNOSTIC IMAGING; EXPERIMENTAL MOUSE; GENE CONTROL; GENETIC SUSCEPTIBILITY; IN VIVO STUDY; KNOCKOUT MOUSE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRESS; TECHNOLOGY; TRANSGENIC MOUSE; TREATMENT INDICATION; TUMOR PROMOTION;

EID: 4143127726     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.05.013     Document Type: Article

References (94)

1. Humphreys S.R., Mantel N., Goldin A. Chemotherapy and surgery of spontaneous tumours of mice. Eur. J. Cancer. 2:1966;1-7
2. Shubik P. The growth potentialities of induced skin tumours in mice; the effects of different methods of chemical carcinogenesis. Cancer Res. 10:1950;713-717
3. Hennings H., Boultwell R.K. Studies on the mechanism of skin tumour promotion. Cancer Res. 30(2):1970;312-320
4. Watson JD, Berry A. DNA: The Secret of Life April 2003 publication. Random House Trade ISBN 0-375-41546-7
5. Stehelin D., Varmus H.E., Bishop J.M., Vogt P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 260:1976;170-173
6. Shih C., Shilo B.Z., Goldfarb M.P., Dannenberg A., Weinberg R.A. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl. Acad. Sci. USA. 76(11):1979;5714-5718
7. Cooper G.M., Neiman P.E. Transforming genes of neoplasms induced by avian lymphoid leukosis viruses. Nature. 287(5783):1980;656-659
8. Wigler M., Perucho M., Kurtz D., Dana S., Pellicer A., Axel R., et al. Transformation of mammalian cells with an amplifiable dominant-acting gene. Proc. Natl. Acad. Sci. USA. 77(6):1980;3567-3570
9. Tabin C.J., Bradley S.M., Bargmann C.I., et al. Mechanism of activation of a human oncogene. Nature. 300(5888):1982;143-149
10. Reddy E.P., Reynolds R.K., Santos E., Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 300(5888):1982;149-152
11. Taparowsky E., Suard Y., Fasano O., Shimizu K., Goldfarb M., Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature. 300(5894):1982;762-765
12. Balmain A., Pragnell I.B. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature. 303(5912):1983;72-74
13. Sukumar S., Notario V., Martin-Zanca D., Barbacid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature. 306(5944):1983;658-661
14. Balmain A., Ramsden M., Bowden G.T., Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature. 307(5952):1984;658-660
15. Quintanilla M., Brown K., Ramsden M., Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 322(6074):1986;78-80
16. Balmain A., Harris C.C. Carcinogenesis in mouse and human cells, parallels and paradoxes. Carcinogenesis. 21(3):2000;371-377
17. Brinster R.L., Chen H.Y., Messing A., van Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumours. Cell. 37(2):1984;367-379
18. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 38(3):1984;627-637
19. Leder A., Pattengale P.K., Kuo A., Stewart T.A., Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice, multiple neoplasms and normal development. Cell. 45(4):1986;485-495
20. Robertson E., Bradley A., Kuehn M., Evans M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature. 323(6087):1986;445-448
21. Thomas K.R., Capecchi M.R. Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature. 324(6092):1986;34-38
22. Doetschman T., Maeda N., Smithies O. Targeted mutation of the Hprt gene in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA. 85(22):1988;8583-8587
23. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356(6366):1992;215-221
24. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A. Weinberg RA effects of an RB mutation in the mouse. Nature. 359(6393):1992;295-300
25. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell. 74(5):1993;813-822
26. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumour suppression and cell mortality. Cell. 85(1):1996;27-37
27. Herzig M., Christofori G. Recent advances in cancer research, mouse models of tumourigenesis. Biochim. Biophys. Acta. 1602(2):2002;97-113
28. Williams B.O., Remington L., Albert D.M., Mukai S., Bronson R.T., Jacks T. Cooperative tumorigenic effects of germline mutations in RB and p53. Nat. Genet. 7(4):1994;480-484
29. Brodie S.G., Xu X., Qiao W., Li W.M., Cao L., Deng C.X. Multiple genetic changes are associated with mammary tumorigenesis in BRCA1 conditional knockout mice. Oncogene. 20(51):2001;7514-7523
30. Jonkers J., Berns A. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer. 2(4):2002;251-265
31. Chan I.T., Kutok J.L., Williams I.R., et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113(4):2004;528-538
32. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400(6743):1999;468-472
33. Baron U., Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells, principles and advances. Methods Enzymol. 327:2000;401-421
34. Eilers M., Picard D., Yamamoto K.R., Bishop J.M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 340(6228):1989;66-68
35. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin, induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. 3(5):1999;565-577
36. Kuhn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science. 269(5229):1995;1427-1429
37. Metzger D., Feil R. Engineering the mouse genome by site-specific recombination. Curr. Opin. Biotechnol. 10(5):1999;470-476
38. Vooijs M., Jonkers J., Lyons S., Berns A. Non-invasive imaging of spontaneous retinoblastoma pathway-dependent tumours in mice. Cancer Res. 62(6):2002;1862-1867
39. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumour suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29(4):2001;418-425
40. Haase V.H., Glickman J.N., Socolovsky M., Jaenisch R. Vascular tumours in livers with targeted inactivation of the von Hippel-Lindau tumour suppressor. Proc. Natl. Acad. Sci. USA. 98(4):2001;1583-1588
41. Giovannini M., Robanus-Maandag E., van der Valk M., Niwa-Kawakita M., Abramowski V., Goutebroze L., et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14(13):2000;1617-1630
42. Xu X., Wagner K.U., Larson D., Weaver Z., Li C., Ried T., et al. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22(1):1999;37-43
43. Meuwissen R., Linn S.C., van der Valk M., Mooi W.J., Berns A. Mouse model for lung tumourigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene. 20(45):2001;6551-6558
44. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumour initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15(24):2001;3243-3248
45. Shibata H., Toyama K., Shioya H., Ito M., Hirota M., Hasegawa S., et al. Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene. Science. 278(5335):1997;120-123
46. Ramirez-Solis R., Liu P., Bradley A. Chromosome engineering in mice. Nature. 378(6558):1995;720-724
47. Yu Y., Bradley A. Engineering chromosomal rearrangements in mice. Nat. Rev. Genet. 2(10):2001;780-790
48. Buchholz F., Refaeli Y., Trumpp A., Bishop J.M. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep. 1(2):2000;133-139
49. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410(6832):2001;1111-1116
50. Hasty P., Ramirez-Solis R., Krumlauf R., Bradley A. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature. 350(6315):1991;243-246
51. Holland E.C. Gliommagenesis, genetic alterations and mouse models. Nat. Rev. Genet. 2(2):2001;120-129
52. Meuwissen R., Linn S.C., Linnoila R.I., Zevenhoven J., Mooi W.J., Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and RB1 in a conditional mouse model. Cancer Cell. 4(3):2003;181-189
53. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25(1):2000;55-57
54. Xiao A., Wu H., Pandolfi P.P., Louis D.N., Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1(2):2002;157-168
55. Ludwig T., Fisher P., Murty V., Efstratiadis A. Development of mammary adenocarcinomas by tissue-specific knockout of BRCA2 in mice. Oncogene. 20(30):2001;3937-3948
56. Hingorani S.R., Petricoin E.F., Maitra A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4(6):2003;437-450
57. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., et al. Activated K-ras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17(24):2003;3112-31126
58. Weissleder R. Scaling down imaging, molecular mapping of cancer in mice. Nat. Rev. Cancer. 2(1):2002;11-18
59. Fisher G.H., Wellen S.L., Klimsta D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a kras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15(24):2001;3249-3262
60. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects, seeing fundamental biological processes in a new light. Genes Dev. 17(5):2003;545-580
61. Haubner R., Wester H.J., Weber W.A., et al. Non-invasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61(5):2001;1781-1785
62. Herschman H.R. Micro-PET imaging and small animal models of disease. Curr. Opin. Immunol. 15(4):2003;378-384
63. Gambhir S.S., Barrio J.R., Wu L., Iyer M., Namavari M., Satyamurthy N., et al. Imaging of adenoviral-directed herpes simplex virus type1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J. Nucl. Med. 39(11):1998;2003-2011
64. Edinger M., Sweeney T.J., Tucker A.A., Olomu A.B., Negrin R.S., Contag C.H. Non-invasive assessment of tumour cell proliferation in animal models. Neoplasia. 1(4):1999;303-310
65. Hennings H., Glick A.B., Greenhalgh D.A., Morgan D.L., Strickland J.E., Tennenbaum T., et al. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc. Soc. Exp. Biol. Med. 202(1):1993;1-8
66. Perez-Losada J., Balmain A. Stem-cell hierarchy in skin cancer. Nat. Rev. Cancer. 3(6):2003;434-443
67. ′-nitro-N-nitrosoguanidine and promoted by mezerein. Mol. Carcinogen. 27(4):2000;298-307
68. Megosh L., Halpern M., Farkash E., O'Brien T.G. Analysis of ras gene mutational spectra in epidermal papillomas from K6/ODC transgenic mice. Mol. Carcinogen. 22(3):1998;145-149
69. Aydinlik H., Nguyen T.D., Moennikes O., Buchmann A., Schwarz M. Selective pressure during tumour promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumours. Oncogene. 20(53):2001;7812-7816
70. Viaje A., Slaga T.J., Wigler M., Weinstein I.B. Effects of anti-inflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator. Cancer Res. 37(5):1977;1530-1536
71. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18(55):1999;7908-7916
72. Shiff S.J., Shivaprasad P., Santini D.L. Cyclooxygenase inhibitors, drugs for cancer prevention. Curr. Opin. Pharmacol. 3(4):2003;352-361
73. Ponder B.A. Cancer genetics. Nature. 411(6835):2001;336-341
74. Peto J. Cancer epidemiology in the last century and the next decade. Nature. 411(6835):2001;390-395
75. Balmain A. Cancer as a complex genetic trait, tumour susceptibility in humans and mouse models. Cell. 108(2):2002;145-152
76. Demant P. Cancer susceptibility in the mouse, genetics, biology and implications for human cancer. Nat. Rev. Genet. 4(9):2003;721-734
77. Mao J.H., Balmain A. Genomic approaches to identification of tumour-susceptibility genes using mouse models. Curr. Opin. Genet. Dev. 13(1):2003;14-19
78. Tripodis N., Hart A.A., Fijneman R.J., Demant P. Complexity of lung cancer modifiers, mapping of 30 genes and 25 interactions in half of the mouse genome. J. Natl. Cancer Inst. 93(19):2001;1484-1491
79. Nagase H., Mao J.H., de Koning J.P., Minami T., Balmain A. Epistatic interactions between skin tumour modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res. 61(4):2001;1305-1308
80. Mott R., Flint J. Simultaneous detection and fine mapping of quantitative trait loci in mice using heterogeneous stocks. Genetics. 160(4):2002;1609-1618
81. Ewart-Toland A., Briassouli P., de Koning J.P., et al. Identification of Stk6/STK15 as a candidate low-penetrance tumour-susceptibility gene in mouse and human. Nat. Genet. 34(4):2003;403-412
82. Ruivenkamp C.A., van Wezel T., Zanon C., et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. 31(3):2002;295-300
83. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284(5415):1999;808-812
84. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100(1):2000;57-70
85. Ganss R., Hanahan D. Tumour microenvironment can restrict the effectiveness of activated antitumour lymphocytes. Cancer Res. 58(20):1998;4673-4681
86. Girardi M., Oppenheim D.E., Steele C.R., et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 294(5542):2001;605-609
87. Hanahan D., Lanzavecchia A., Mihich E. Fourteenth annual pezcoller symposium, the novel dichotomy of immune interactions with tumours. Cancer Res. 63(11):2003;3005-3008
88. Staelens J., Wielockx B., Puimege L., Van Roy F., Guenet J.L., Libert C. Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumour necrosis factor and implications for a TNF-based antitumour therapy. Proc. Natl. Acad. Sci. USA. 99(14):2002;9340-9345
89. Anderson A. Oncomouse released. Nature. 336(6197):1988;300
90. Marshall E. Intellectual property. NIH cuts deal on use of OncoMouse. Science. 287(5453):2000;567
91. Marshall E. Intellectual property. DuPont ups ante on use of Harvard's OncoMouse. Science. 296(5571):2002;1212-1213
92. Scholler F.S., Philips F.S., Sternberg S.S., Bittner J.J. A comparative study of chemotherapeutic agents in spontaneous mammary adenocarcinomas of mice and in transplants of recent origin. Cancer. 9(2):1956;240-251
93. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293(5531):2001;876-880
94. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571, a prospective study. Lancet. 9359(9305):2002;487-491